This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items


Schmitt, Frederick A., Aarsland, Dag, Brønnick, Kolbjørn S., Meng, Xiangyi, Tekin, Sibel, Olin, Jason T.


American Journal of Alzheimer's Disease and Other Dementias, Volume: 25, No.: 5, Pages.: 407-413

Year of Publication



Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 to 12 mg/d rivastigmine capsules and 179 to placebo. Patients with PDD receiving rivastigmine improved versus placebo on items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language (P < .05), with standardized mean differences ranging from 0.04 to 0.30. Rivastigmine also showed significant effects versus placebo on all domains: memory, language, and praxis. The ADAS-cog is sensitive to broad cognitive changes in PDD. Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Schmitt_2010, doi = {10.1177/1533317510367486}, url = {}, year = 2010, month = {apr}, publisher = {{SAGE} Publications}, volume = {25}, number = {5}, pages = {407--413}, author = {F. A. Schmitt and D. Aarsland and K. S. Bronnick and Xiangyi Meng and S. Tekin and J. T. Olin}, title = {Evaluating Rivastigmine in Mild-to-Moderate Parkinson{textquotesingle}s Disease Dementia Using {ADAS}-Cog Items}, journal = {American Journal of Alzheimer{textquotesingle}s Disease and Other Dementias} }


alzheimer’s disease, alzheimers disease assessment scalecognitive subscale, cognition, dementia, drug therapy, parkinsons disease, rivastigimine, rivastigmine

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime